Development of Peptide-Based Vaccines for Cancer
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Peptides cancer vaccines are designed based on the epitope peptides that can elicit humoral and cellular immune responses targeting tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs). In order to develop a clinically safe and more effective vaccine for the future, several issues need to be addressed, and these include the selection of optimal antigen targets, adjuvants, and immunization regimens. Another emerging approach involves the use of personalized peptide-based vaccines based on neoantigens to enhance antitumor response. Rationally designed combinatorial therapy is currently being investigated with chemotherapeutic drugs or immune checkpoint inhibitor therapies to improve the efficacy. This review discusses an overview of the development of peptide-based vaccines, the role of adjuvants, and the delivery systems for peptide vaccines as well as combinatorial therapy as potential anticancer strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021641 · Cited by 6,249
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 1×
“+e vaccine approval was based on the success of a placebo-control study involving 512 patients randomly assigned to receive sipuleucel-Tor placebo in a 2 :1 ratio [11].”
MethodPoly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816 · cited 1×
“Poly (lacticco-glycolic acid) (PLGA) and liposomes are examples of drug delivery applications that have been studied experimentally for many years and had proven history in terms of safety and biodegradability, with the FDA approving their usage as drug delivery systems [98].”
BackgroundAn immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936 · cited 2×
“Two-thirds of the patients showed clinical responses ranging from no recurrence to a reduction in metastasis [59].”
BackgroundImmune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035 · cited 1×
“ICIs have been proven to enhance the existing antitumor immune response by targeting the immune checkpoints and promoting immune-mediated eradication of tumor cells [138].”
BackgroundTam, J. P. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.15.5409 · Cited by 1,251 · cited 1×
“Four or eight copies of peptides were attached to a core comprising lysine residues, thus producing a branched peptide tree with a molecular weight of a small protein [52].”
BackgroundIdentification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
Molecular biology of human papillomavirus infection and cervical cancer
Doorbar, J. (2006) · Clinical Science · doi:10.1042/cs20050369 · Cited by 1,072 · cited 1×
“Gardasil and Cervarix, on the other hand, are generated from VLPs consisting of the single capsid protein L1, which provides protection against HPV types 16 and 18 [4].”
BackgroundAdvances in the development of personalized neoantigen-based therapeutic cancer vaccines
Blass, E., & Ott, P. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00460-2 · Cited by 1,042
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Actively personalized vaccination trial for newly diagnosed glioblastoma
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature · doi:10.1038/s41586-018-0810-y · Cited by 938 · cited 7×
“However, to date, immunostimulatory cytokines such as GM-CSF is the most common adjuvant being used in anticancer peptide vaccination trials as it could enhance effective priming of T cell responses by attracting and stimulating DCs [88, 91, 92].”
BackgroundInfluentialOtt, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.053 · Cited by 738 · cited 1×
“Different studies evaluated a personal neoantigen vaccine (NEO-PV-01) in combination with nivolumab in patients with advanced melanoma, NSCLC, or bladder cancer in a phase 1b clinical trial (NCT02897765) [144].”
BackgroundTurning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689
Peptide-based synthetic vaccines
Skwarczynski, M., & Toth, I. (2016) · Chemical Science · doi:10.1039/c5sc03892h · Cited by 596 · cited 1×
“Delivery systems are often defined as self-adjuvanting or having a built-in adjuvant that could be administered or transported, while adjuvants are substances with the ability to induce an immune response against the antigen of interest [71].”
BackgroundWeber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4802 · Cited by 535
Signalling strength determines proapoptotic functions of STING
Gulen, M. F., Koch, U., Haag, S. M., Schuler, F., Apetoh, L., Villunger, A., Radtke, F., & Ablasser, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00573-w · Cited by 505
Massarelli, E., William, W., Johnson, F., Kies, M., Ferrarotto, R., Guo, M., Feng, L., Lee, J. J., Tran, H., Kim, Y. U., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4051 · Cited by 490 · cited 1×
“5 months when compared to 20% overall response rate and median survival of approximately 9 months with nivolumab alone in similar patients with advanced cervical cancer [143].”
BackgroundThe Peptide Vaccine of the Future
Nelde, A., Rammensee, H.-G., & Walz, J. S. (2021) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r120.002309 · Cited by 205
Cancer Vaccines, Adjuvants, and Delivery Systems
Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627932 · Cited by 200
Kono, K., Sato, E., Naganuma, H., Takahashi, A., Mimura, K., Nukui, H., & Fujii, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0424 · Cited by 59 · cited 1×
“Trastuzumab, an anti-HER-2 monoclonal antibody, was used to treat breast cancer and had been found to cause HER-2-positive tumor cells to become more susceptible to antibody-dependent and T cell-mediated cytotoxicity [128, 129].”
Method
Cited by
Ye, L., Zhao, G., Ma, J., Gan, Q., Luo, N., Pan, D., Chen, C., Chen, X., & Ning, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02769-3 · Cited by 10
“158,159 Personalized DC cancer vaccines .”
β-amino acid substitution in the SIINFEKL antigen alters immunological recognition
Rastogi, I., Mannone, J. A., Gibadullin, R., Moseman, J. E., Sidney, J., Sette, A., McNeel, D. G., & Gellman, S. H. (2025) · Cancer Biology & Therapy · doi:10.1080/15384047.2025.2486141 · Cited by 5
Brlek, P., Kolić, J., Bulić, L., Škaro, V., & Primorac, D. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1875066 · Cited by 1
Al-Omari, A. A., Cook, K. W., Symonds, P., Skinner, A., Wright, A., Zhu, Y., Coble, V. L., Mohammed, O. J., Choudhury, R. H., Uddin, N., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-01029-1
Metadata
- Authors
- Abd-Aziz, N., & Poh, C. L.
- Venue
- Journal of Oncology
- Publisher
- Wiley
- Published
- 2022-03-15
- Volume
- 2022
- Pages
- 1-17
- ISSN
- 1687-8450 (ISSN-L)
- 1687-8469
- OpenAlex
- W4220782974
- Cited by
- 152
- References
- 23
- FWCI
- 9.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.